Insider · CIK 0001197020
Vicki L Sato
Files at VIR (Vir Biotechnology, Inc.), DNLI (Denali Therapeutics Inc.), ALLO (Allogene Therapeutics, Inc.). First filing Nov 5, 2024, latest Jan 3, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNLI: Denali Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Denali Therapeutics Inc. | $64k 3,080 shares | -3% | - | |
| 15Weak | Denali Therapeutics Inc. | $31k 1,020 shares | -1% | - | |
| 19Weak | Denali Therapeutics Inc. | $83k 3,080 shares | -3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +144,400 | $0.00 | $0 | 144,400 | Jun 23, 2025 |
| May 30, 2025 | VIR Vir Biotechnology, Inc. | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 1,320,391 | Jun 2, 2025 |
| May 30, 2025 | VIR Vir Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
| Jan 2, 2025 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -3,080 | $20.91 | $64k | 107,976 | Jan 3, 2025 |
| Nov 7, 2024 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -1,020 | $30.00 | $31k | 111,056 | Nov 12, 2024 |
| Nov 1, 2024 | DNLI Denali Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -3,080 | $27.07 | $83k | 112,076 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.